Gruppo Italiano Trapianto di Midollo Osseo
19
1
3
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
11%
2 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Role: collaborator
GITMO AML/MDS-Relapse Registry Study
Role: lead
Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT
Role: lead
Pentaglobin in CRE and PA Neutropenic Infections
Role: lead
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
Role: lead
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma
Role: lead
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
Role: lead
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
Role: lead
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD
Role: lead
A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia
Role: lead
Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant
Role: lead
A Prospective Observational Study for Evaluating CGVHD
Role: lead
DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Role: lead
High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT
Role: lead
Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis
Role: lead
ALLO-SCT in Elderly Patients With Hematological Disease
Role: lead
Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant
Role: lead
SCT in Ph Positive Acute Lymphoblastic Leukemia
Role: collaborator
Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
Role: collaborator
All 19 trials loaded